Research by Professor Wedzicha of the National Heart and Lung Institute (NHLI) discover better mixture and combination therapy for COPD exacerbations Treatment: It is rumination that there are nearly 3 million people in the UK who suffer with chronic obstructive pulmonary disorder, more repeatedly called COPD. Patients are mostly distressed by COPD Exacerbations where they see a unanticipated exacerbate of their symptoms, such as breathlessness, with the capacity to develop or happen in the future triggered by an infection or air pollutants. To combat this, patients are placed on treatment plans to try to manage the prevalence of these intermittence and ultimately reduce their occurrence.
Currently there are two options recommended for prevention of this disease. Either inhaled corticosteroids (ICS) with long acting Beta 2 agonists (LABA), or an inhaled long-acting muscarinic anatagonist (LAMA). To date a combination of the two regimes had not been compared to find the best results for patients.New research by Professor Wedzicha of the National Heart and Lung Institute is the first study to compare two combination therapies to COPD exacerbations Treatment patients at risk of exacerbations.